Table 2.
Distribution of CEUS enhancement patterns and prognostic factors.
| CEUS performance | ERG1 | ERG2 | PRG1 | PRG2 | Ki-67G1 | Ki-67G2 | P53G1 | P53G2 | c-er-B2G1 | c-er-B2G2 | VEGFG1 | VEGFG2 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| + | − | + | − | + | − | + | − | + | − | + | − | + | − | + | − | + | − | + | − | + | − | + | − | |
| Enhancement degree | ||||||||||||||||||||||||
| Hyperenhancement | 28 | 10 | 29 | 17 | 26 | 12 | 26 | 20 | 24 | 14 | 35 | 11 | 30 | 8 | 38 | 8 | 20 | 19 | 31 | 20 | 21 | 17 | 19 | 27 |
| Iso- or hypoenhancement | 6 | 3 | 6 | 5 | 6 | 3 | 6 | 5 | 4 | 5 | 7 | 4 | 5 | 4 | 8 | 3 | 1 | 7 | 1 | 5 | 6 | 3 | 7 | 4 |
| Enhancement order | ||||||||||||||||||||||||
| Centripetal | 20 | 12 | 24 | 11 | 21 | 11 | 12 | 13 | 17 | 15 | 26 | 9 | 23 | 9 | 29 | 6 | 17 | 15 | 20 | 15 | 19 | 13 | 12 | 23 |
| Centrifugal or diffuse | 14 | 1 | 11 | 11 | 11 | 4 | 10 | 22 | 11 | 4 | 16 | 6 | 12 | 3 | 17 | 5 | 4 | 11 | 12 | 10 | 8 | 7 | 14 | 8 |
| Penetrating vessels | ||||||||||||||||||||||||
| Present | 17 | 6 | 19 | 5 | 16 | 7 | 17 | 7 | 15 | 8 | 20 | 4 | 17 | 6 | 20 | 4 | 9 | 13 | 16 | 8 | 15 | 8 | 15 | 9 |
| Absent | 17 | 7 | 16 | 17 | 16 | 8 | 15 | 18 | 13 | 11 | 22 | 11 | 18 | 6 | 26 | 7 | 13 | 13 | 16 | 17 | 12 | 12 | 11 | 22 |
| Enhancement pattern | ||||||||||||||||||||||||
| Heterogeneous | 6 | 5 | 21 | 16 | 7 | 4 | 20 | 17 | 6 | 5 | 28 | 9 | 6 | 5 | 29 | 8 | 10 | 12 | 19 | 16 | 5 | 6 | 14 | 23 |
| Homogeneous | 28 | 8 | 14 | 6 | 25 | 11 | 12 | 8 | 22 | 14 | 14 | 6 | 29 | 7 | 17 | 3 | 11 | 14 | 13 | 9 | 22 | 14 | 12 | 8 |
| Enhancement area | ||||||||||||||||||||||||
| Enlargement | 27 | 6 | 25 | 14 | 23 | 10 | 22 | 17 | 21 | 12 | 30 | 9 | 26 | 7 | 32 | 7 | 17 | 16 | 25 | 14 | 21 | 12 | 19 | 20 |
| Nonenlargement | 7 | 7 | 10 | 8 | 9 | 5 | 10 | 8 | 7 | 7 | 12 | 6 | 9 | 5 | 14 | 4 | 4 | 10 | 7 | 11 | 6 | 8 | 7 | 11 |
Note: data are the number of cases. G1: Group 1; G2: Group 2.